DK2030625T3 - Anvendelse af actinomyceter til behandling af type II-diabetes - Google Patents

Anvendelse af actinomyceter til behandling af type II-diabetes

Info

Publication number
DK2030625T3
DK2030625T3 DK08252833.2T DK08252833T DK2030625T3 DK 2030625 T3 DK2030625 T3 DK 2030625T3 DK 08252833 T DK08252833 T DK 08252833T DK 2030625 T3 DK2030625 T3 DK 2030625T3
Authority
DK
Denmark
Prior art keywords
diabetes
treatment
type
actinomycetes
genera
Prior art date
Application number
DK08252833.2T
Other languages
English (en)
Inventor
John Lawson Stanford
Graham Mcintyre
Oscar Adelmo Bottasso
Cynthia Stanford
Original Assignee
Bioeos Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioeos Ltd filed Critical Bioeos Ltd
Application granted granted Critical
Publication of DK2030625T3 publication Critical patent/DK2030625T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Lubricants (AREA)
DK08252833.2T 2007-08-29 2008-08-27 Anvendelse af actinomyceter til behandling af type II-diabetes DK2030625T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0716778.6A GB0716778D0 (en) 2007-08-29 2007-08-29 Use

Publications (1)

Publication Number Publication Date
DK2030625T3 true DK2030625T3 (da) 2010-06-07

Family

ID=38616918

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08252833.2T DK2030625T3 (da) 2007-08-29 2008-08-27 Anvendelse af actinomyceter til behandling af type II-diabetes

Country Status (9)

Country Link
US (1) US8349314B2 (da)
EP (1) EP2030625B1 (da)
JP (1) JP5523685B2 (da)
AT (1) ATE460172T1 (da)
CA (1) CA2639129C (da)
DE (1) DE602008000779D1 (da)
DK (1) DK2030625T3 (da)
ES (1) ES2341741T3 (da)
GB (1) GB0716778D0 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101703528B (zh) * 2009-11-25 2012-07-04 王立平 一种治疗糖尿病的复合微生物制剂及其制备方法和应用
US12102654B2 (en) * 2019-01-15 2024-10-01 Liaoning Greatest Bio-Pharmaceutical Co., Ltd. Product derived from Rhodococcus ruber, and pharmaceutical use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0631283B2 (ja) * 1987-04-07 1994-04-27 武田薬品工業株式会社 生理活性物質ｆａ−１８１９，その製造法およびそれを含有する治療剤
US5629200A (en) 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5629194A (en) 1994-10-21 1997-05-13 Diacrin, Inc. Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
GB9505658D0 (en) 1995-03-21 1995-05-10 Univ London Hormone and growth factor mimetics
GB0025694D0 (en) 2000-10-19 2000-12-06 Univ London Vaccine
US20060062807A1 (en) * 2001-12-11 2006-03-23 Marie-Anne Nahori Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
AR041171A1 (es) 2002-09-06 2005-05-04 Univ London Modulador inmune
ATE473014T1 (de) 2003-11-14 2010-07-15 Ucl Business Plc Immunmodulator mit ganzzell-tsukamurella bakterien
US20070135504A1 (en) * 2005-12-11 2007-06-14 Marshall Trevor G Method of Treating and/or Preventing Inflammatory Diseases, including many Autoimmune and Neurological diseases, using drugs to modulate the VDR, and/or PPAR, and/or GCR and/or CB1 nuclear and GPCR receptors; in conjunction with antibiotics which target prokaryotic protein translation
GB0526032D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Use
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
GB0526031D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Use
JP5645409B2 (ja) * 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連疾患の治療方法

Also Published As

Publication number Publication date
DE602008000779D1 (de) 2010-04-22
GB0716778D0 (en) 2007-10-10
JP5523685B2 (ja) 2014-06-18
CA2639129A1 (en) 2009-02-28
JP2009067792A (ja) 2009-04-02
ATE460172T1 (de) 2010-03-15
CA2639129C (en) 2017-03-28
ES2341741T3 (es) 2010-06-25
EP2030625A1 (en) 2009-03-04
EP2030625B1 (en) 2010-03-10
US8349314B2 (en) 2013-01-08
US20090060877A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
Ahn et al. N2O emissions from activated sludge processes, 2008− 2009: results of a national monitoring survey in the United States
Chakraborty et al. Biodegradation of phenol by native microorganisms isolated from coke processing wastewater
Campbell et al. Model of the molecular basis for hydroxylamine oxidation and nitrous oxide production in methanotrophic bacteria
Ontiveros-Valencia et al. Interactions between nitrate-reducing and sulfate-reducing bacteria coexisting in a hydrogen-fed biofilm
Da Silva et al. Assessment of bacterial and archaeal community structure in swine wastewater treatment processes
Liu et al. Prokaryotic diversity, composition structure, and phylogenetic analysis of microbial communities in leachate sediment ecosystems
Xie et al. Nitrogen removal through different pathways in an aged refuse bioreactor treating mature landfill leachate
Zhang et al. Effect of dechlorination and sulfate reduction on the microbial community structure in denitrifying membrane-biofilm reactors
Gao et al. Predictive functional profiling using marker gene sequences and community diversity analyses of microbes in full-scale anaerobic sludge digesters
Hidaka et al. The presence of nitrate-and sulfate-reducing bacteria contributes to ineffectiveness souring control by nitrate injection
Hu et al. Anaerobic biodegradation of partially hydrolyzed polyacrylamide in long-term methanogenic enrichment cultures from production water of oil reservoirs
AR079582A1 (es) Proceso de biodegradacion empleando composicion microbiana
WO2011002683A3 (en) High performance nitrifying sludge for high ammonium concentration and low temperature wastewater treatment
MX2009002658A (es) Un metodo para mejorar el desempeño de un bioreactor de membranas.
Xiong et al. Microbial community analysis provides insights into the effects of tetrahydrofuran on 1, 4-dioxane biodegradation
Kasai et al. Degradative capacities and bioaugmentation potential of an anaerobic benzene-degrading bacterium strain DN11
Zhou et al. Practical applications of PCR primers in detection of anammox bacteria effectively from different types of samples
Flores et al. Effects of Benzalkonium Chloride, Proxel LV, P3 Hypochloran, Triton X-100 and DOWFAX 63N10 on anaerobic digestion processes
Prachakittikul et al. ANAMMOX-like performances for nitrogen removal from ammonium-sulfate-rich wastewater in an anaerobic sequencing batch reactor
Gao et al. Changes of abundance and diversity of ammonia-oxidizing archaea (AOA) and bacteria (AOB) in three nitrifying bioreactors with different ammonia concentrations
Vishnivetskaya et al. Microbial communities involved in biological ammonium removal from coal combustion wastewaters
Biswas et al. dsrAB-based analysis of sulphate-reducing bacteria in moving bed biofilm reactor (MBBR) wastewater treatment plants
Motteran et al. Kinetics of methane production and biodegradation of linear alkylbenzene sulfonate from laundry wastewater
Yao et al. The effect of tetrahydrofuran on the enzymatic activity and microbial community in activated sludge from a sequencing batch reactor
Jones et al. Characterization of a microbial consortium capable of rapid and simultaneous dechlorination of 1, 1, 2, 2-tetrachloroethane and chlorinated ethane and ethene intermediates